United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

24 Feb 2017
Change (% chg)

$0.10 (+3.83%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

ImmunoGen Inc Appoints Mark J. Enyedy as President and Chief Executive Officer
Tuesday, 26 Apr 2016 08:00am EDT 

ImmunoGen Inc:Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16.Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.  Full Article

ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with keytruda
Thursday, 4 Feb 2016 08:00am EST 

ImmunoGen Inc:Says the company and Merck have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy.Says agreement is between immunogen and Merck, through a subsidiary.Says agreement includes a provision for potential expansion of the collaboration to include a subsequent phase 3 clinical trial.Additional details were not disclosed.  Full Article

ImmunoGen Inc gives FY 2016 guidance
Friday, 31 Jul 2015 06:30am EDT 

ImmunoGen Inc:Says that it expects FY 2016 revenues to be between $70 million and $80 million.Sees FY 2015 net loss to be between $120 million and $125 million.  Full Article

ImmunoGen Inc reaffirms FY 2015 net loss outlook, lowers revenue outlook
Friday, 24 Apr 2015 06:17am EDT 

ImmunoGen Inc:Continues to expect FY 2015 net loss between $60 and $65 million.Now expects FY 2015 revenues to be between $85 and $95 million, compared with previous guidance of between $100 and $105 million, due to changes in the expected timing of partner milestone events.  Full Article

ImmunoGen Inc and Hurricane LLC enters into royalty purchase agreement with Immunity Royalty Holdings - Form 8-K
Monday, 30 Mar 2015 08:02am EDT 

ImmunoGen Inc:Says company and its wholly owned subsidiary, Hurricane, LLC entered into a royalty purchase agreement with Immunity Royalty Holdings, L.P (purchaser)., which was formed by certain TPG Special Situations Partners’ investment funds.Transaction is subject to the satisfaction of customary closing conditions and is expected to close in early April.Purchase Agreement provides that, in consideration of the payment of $200 mln by the Purchaser to Hurricane.Purchaser will have the right to receive 100 pct of the royalty payments on commercial sales of Kadcyla (Kadcyla Royalties) arising under License Agreement with Genentech, Inc., as amended, until the Purchaser has received aggregate Kadcyla Royalties equal to $235 mln or $260 mln;.Depending on when the aggregate Kadcyla Royalties received by the Purchaser reach a specified milestone.Once the applicable threshold is met, if ever, we will thereafter receive 85 pct, and the Purchaser will receive 15 pct, of the Kadcyla Royalties for the remaining royalty term.  Full Article

Takeda Pharmaceutical announces business alliance with ImmunoGen
Monday, 23 Mar 2015 07:00pm EDT 

Takeda Pharmaceutical Co Ltd:Formed a business alliance of exclusive license of antibody-drug conjugate, which is owned by Takeda Pharmaceutical, with ImmunoGen Inc.  Full Article

More From Around the Web

BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln

* Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016